Cancer Research UK, the University of Manchester and AstraZeneca have signed two new deals on developing cancer drugs.
News
Celgene gets fresh Revlimid OK, pomalidomide impresses again
Another busy weekend for Celgene saw the firm get European approval for Revlimid as a treatment for a rare form of blood disease and present more promising data on its multiple myeloma drug pomalidomide.
Cervical cancer cases slashed with HPV test
Around a third of cervical cancer cases could be prevented every year in England if women were tested for human papilloma virus (HPV), researchers are claiming.
Elan raises eyebrows with ‘for sale’ move
The Elan-Royalty Pharma takeover saga has taken yet another turn after the Irish drugmaker announced that it is now officially up for sale.
Positive survival data for B-MS/AbbVie’s blood cancer drug
Bristol-Myers Squibb and AbbVie have unveiled new data from a mid-stage trial of their experimental monoclonal antibody elotuzumab, raising hopes that the drug could offer a signifiant benefit in progression-free survival (PFS) in patients with the blood cancer multiple myeloma.
Discount sees NICE yes for Alimera’s Iluvien
In draft guidance published today NICE says it is recommending Alimera’s Iluvien for certain patients with chronic diabetic macular oedema after the firm offered a price cut for its treatment.
Lilly halts AD trial, baricitinib impresses in RA
Eli Lilly has stopped a Phase II study for an investigational Alzheimer’s disease treatment due to potential liver problems.
Spain’s austerity healthcare cuts “putting lives at risk”
The austerity reforms being made by the Spanish government could lead to the effective dismantling of large parts of the country’s healthcare system, with potentially detrimental effects on the health of the Spanish people, researchers have warned, writing in the British Medical Journal (BMJ).
US Supremes compromise in landmark gene patent case
In an eagerly-watched case that will have a major bearing on future medical research, the US Supreme Court has ruled that human genes cannot be patented, but synthetic, or complementary, DNA can be.
New PhIII data raises hopes for Celgene’s apremilast
Celgene has unveiled late-stage data showing that its experimental drug apremilast induced “meaningful improvements” in the signs and symptoms of psoriatic arthritis in the long term, adding further weight to the package of data being used to seek regulatory approval.
NICE still backing GSK’s bleeding disorder drug
Patients with the bleeding disorder chronic immune (idiopathic) thrombocytopenic purpura are a giant step closer to being able to access GlaxoSmithKline’s Revolade (eltrombopag) on the National Health Service.
Pfizer/Takeda accept $2.15 billion to settle Protonix case
Pfizer shares were given a lift yesterday after it announced that a near 10-year patent infringement battle over Protonix has been laid to rest with a settlement of $2.15 billion.
Plans to sell drugs on planes and trains under fire
Plans to allow the sale of medicines on planes and trains have hit a snag, after several pharmacy groups voiced concerns over the proposal.
SMC ‘no’ for Alimera’s Iluvien but Almirall drug wins OK
Scottish cost regulators have rejected National Health Service funding for Alimera Science’s eye implant Iluvien in patients with diabetic macular oedema, on grounds that it is too expensive.
US biopharma: “215 heart disease/stroke drugs now in R&D”
US biopharmaceutical companies are currently developing 215 new medicines for heart disease and stroke, according to new industry data.
